Description

Strofantin-Darnitsa (g-strophanthin) solution for injection 0.025% 1ml. ampoules №10

Ingredients:

Each 1ml ampoule contains 0.025% of g-strophanthin as the active ingredient.

Dosage:

The recommended dosage is determined by a healthcare professional and depends on the patient’s condition. It is usually administered via intravenous injection.

Indications:

Strofantin-Darnitsa is indicated for the treatment of heart conditions such as heart failure and atrial fibrillation. It works by increasing the strength of the heart’s contractions.

Contraindications:

Do not use Strofantin-Darnitsa if you are allergic to g-strophanthin or any other ingredients in the solution. It is contraindicated in patients with certain heart conditions.

Directions:

Administer Strofantin-Darnitsa as directed by a healthcare provider. It is important to follow the recommended dosage and administration guidelines.

Scientific Evidence:

Strofantin-Darnitsa has been studied in clinical trials for its efficacy in treating heart conditions. Research has shown that g-strophanthin, the active ingredient in Strofantin-Darnitsa, can improve cardiac function and reduce symptoms of heart failure.

Additional Information:

In addition to its use in heart conditions, Strofantin-Darnitsa may also have potential benefits in other areas of medicine. Further research is ongoing to explore its full therapeutic potential and possible applications in different patient populations.

Pharmacological Effects: Strofantin-Darnitsa works by inhibiting the sodium-potassium pump in cardiac cells, leading to an increase in intracellular calcium levels. This results in enhanced myocardial contractility and improved cardiac output.

Clinical Trials: A study published in the European Journal of Heart Failure demonstrated the efficacy of g-strophanthin in improving left ventricular function in patients with heart failure. The results showed a significant increase in ejection fraction and exercise tolerance in the treatment group compared to placebo.